The TUXEDO-2 trial reveals that ticagrelor did not meet noninferiority criteria compared with prasugrel in diabetic patients with multivessel coronary artery disease undergoing PCI. At 1 year, the primary composite endpoint of death, MI, stroke, or major bleeding occurred in 16.6% vs 14.2% of patients, suggesting prasugrel may offer better outcomes in this high-risk population.